Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

• Status: Completed
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P. falciparum parasite prevalence, confirmed OPD malaria case incidence and cohort infection incidence in areas of high and low malaria transmission and in a program-relevant manner that will permit adoption and adaptation for wider-scale deployment.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: PATH
• Collaborators: Minister of Community Development, Mother and Child Health, Zambia; Ministry of Health, Zambia; Tulane University
• Treatments: Dihydroartemisinin; Piperaquine

Criteria

Inclusion Criteria:

• anyone not excluded and consenting

Exclusion Criteria:

• contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin

• anyone seriously ill

• currently taking antimalarial medicines

• allergy to artemisinin drugs

• pregnant women in first trimester

• children under 3 months of age

• reported heart condition